Merck announces week 96 data from phase 2b study evaluating islatravir in combination with doravirine in adults with hiv-1 infection

Merck announces week 96 data from phase 2b study evaluating islatravir in combination with doravirine in adults with hiv-1 infection
AXDX Ratings Summary
AXDX Quant Ranking